DK1002055T3 - Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning - Google Patents

Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning

Info

Publication number
DK1002055T3
DK1002055T3 DK98938765T DK98938765T DK1002055T3 DK 1002055 T3 DK1002055 T3 DK 1002055T3 DK 98938765 T DK98938765 T DK 98938765T DK 98938765 T DK98938765 T DK 98938765T DK 1002055 T3 DK1002055 T3 DK 1002055T3
Authority
DK
Denmark
Prior art keywords
virus
cell culture
recovery
saline solution
hypertonic saline
Prior art date
Application number
DK98938765T
Other languages
Danish (da)
English (en)
Inventor
Michael Denis Johnston
Roderic Simon O'keeffe
Original Assignee
Xenova Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10817061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1002055(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenova Res Ltd filed Critical Xenova Res Ltd
Application granted granted Critical
Publication of DK1002055T3 publication Critical patent/DK1002055T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98938765T 1997-08-07 1998-08-07 Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning DK1002055T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9716611.0A GB9716611D0 (en) 1997-08-07 1997-08-07 Virus preparations and methods
EP98938765A EP1002055B2 (de) 1997-08-07 1998-08-07 Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung
PCT/GB1998/002387 WO1999007834A1 (en) 1997-08-07 1998-08-07 Recovery of virus from cell culture using a hypertonic salt solution

Publications (1)

Publication Number Publication Date
DK1002055T3 true DK1002055T3 (da) 2004-10-25

Family

ID=10817061

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98938765T DK1002055T3 (da) 1997-08-07 1998-08-07 Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning

Country Status (11)

Country Link
EP (1) EP1002055B2 (de)
JP (2) JP2001512675A (de)
AT (1) ATE270325T1 (de)
AU (1) AU8737298A (de)
CA (1) CA2299628A1 (de)
DE (1) DE69824856T2 (de)
DK (1) DK1002055T3 (de)
ES (1) ES2224422T3 (de)
GB (1) GB9716611D0 (de)
PT (1) PT1002055E (de)
WO (1) WO1999007834A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330202T5 (es) 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
DK1608762T3 (da) 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
DE602004028736D1 (de) * 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
CN100398642C (zh) * 2003-06-20 2008-07-02 迈克必斯生物系统公司 病毒生产的改进
EP1651666B1 (de) 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US7850977B2 (en) 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
JP5980947B2 (ja) 2012-11-22 2016-08-31 旭化成メディカル株式会社 高感染価のパルボウイルスの生産方法
CN104250639A (zh) * 2013-06-28 2014-12-31 北京奥源和力生物技术有限公司 一种收获和生产病毒的方法
EP3372677B8 (de) 2015-11-06 2019-09-25 Asahi Kasei Medical Co., Ltd. Verfahren zur herstellung eines parvovirus mit hohem infektiositätstiter und hoher reinheit
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
BR112022025251A2 (pt) * 2020-07-10 2023-01-17 Boehringer Ingelheim Int Processo para produzir rabdovírus purificado a partir de cultura celular

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204257A (en) * 1991-04-29 1993-04-20 Autogen Instruments, Inc. Method of recovering bacteriophage
WO1993024616A1 (en) * 1992-06-04 1993-12-09 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
EP1002055A1 (de) 2000-05-24
EP1002055B2 (de) 2010-04-14
GB9716611D0 (en) 1997-10-08
ATE270325T1 (de) 2004-07-15
CA2299628A1 (en) 1999-02-18
DE69824856D1 (de) 2004-08-05
ES2224422T3 (es) 2005-03-01
WO1999007834A1 (en) 1999-02-18
JP2001512675A (ja) 2001-08-28
DE69824856T2 (de) 2005-07-21
PT1002055E (pt) 2004-10-29
AU8737298A (en) 1999-03-01
EP1002055B1 (de) 2004-06-30
JP2009297036A (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
DK1002055T3 (da) Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
ATE466932T1 (de) Vermehrung von viren in zellkultur
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
DE60017234D1 (de) Vakzinproduktion
EA200100955A1 (ru) 4-ОКСО-4,7-ДИГИДРОТИЕНО [2,3-b]ПИРИДИН-5-КАРБОКСАМИДЫ В КАЧЕСТВЕ АНТИВИРУСНЫХ СРЕДСТВ
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
UA85543C2 (ru) Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
RU2018101139A (ru) Фармацевтические препараты для лечения вирусных инфекций глаза
EA200300215A1 (ru) Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой
ES336810A1 (es) Un metodo para producir una cepa de celulas.
HUP0101081A2 (hu) Tápközeg és eljárás vírustenyésztésre és szaporításra
KR20070120088A (ko) 바이러스 제제 및 방법
Rosso et al. A model of a cerebral tumour for studies in cancer chemotherapy
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
CN111690688B (zh) 表达靶向REV的CRISPR/Cas9的重组马立克氏病病毒及其应用
CN105561303B (zh) 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
CN105255944A (zh) 基于转opn基因诱导的肝细胞体外增殖方法
CN105535959A (zh) 单纯性疱疹病毒i型ul18基因缺失减活疫苗的制备方法
RU99113870A (ru) Вакцинный штамм вируса краснухи "орлов-д" и способ получения вакцины против краснухи
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
RU2000125010A (ru) Способ получения бивалентной вакцины против болезни марека
TH58175A3 (th) ขั้นตอนสำหรับการเตรียมไวรัสก่อโรคมาเร็คส์โดยการใช้เซลล์สายพันธุ์เอเวียนต่อเนื่อง
EP1327687A4 (de) Verfahren zur infektion des hepatitis c viruses